Stephen Hoge - 27 Feb 2024 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role: President
Signature: /s/ Brian Sandstrom, as Attorney-in-Fact
Issuer symbol: MRNA
Transactions as of: 27 Feb 2024
Net transactions value: $0
Form type: 4
Filing time: 29 Feb 2024, 16:32:01 UTC
Previous filing: 23 Feb 2024
Next filing: 01 Mar 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	MRNA	Common Stock						1,513,433	27 Feb 2024	Direct
holding	MRNA	Common Stock						4,116	27 Feb 2024	By Valhalla, LLC
holding	MRNA	Common Stock						151,933	27 Feb 2024	By Trust	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MRNA	Stock Option (Right to Buy)	Award	$0	+43,894		$0.000000	43,894	27 Feb 2024	Common Stock	43,894	$96.20	Direct	F2
transaction	MRNA	Restricted Stock Units	Award	$0	+22,987		$0.000000	22,987	27 Feb 2024	Common Stock	22,987	$0.000000	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F2	25% of this option will vest and become exercisable on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F3	25% of the shares subject to this restricted stock unit award will vest on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter.